Equities Analysts Issue Forecasts for TSE:TH FY2025 Earnings

Theratechnologies Inc. (TSE:TH) – Equities research analysts at Leede Financial reduced their FY2025 earnings estimates for Theratechnologies in a research note issued on Monday, April 14th. Leede Financial analyst D. Loe now expects that the company will earn ($0.27) per share for the year, down from their previous estimate of $0.09. The consensus estimate for Theratechnologies’ current full-year earnings is $0.03 per share.

A number of other equities research analysts also recently commented on the company. Research Capitl raised Theratechnologies to a “strong-buy” rating in a research report on Friday, February 14th. Jones Trading upgraded Theratechnologies from a “hold” rating to a “strong-buy” rating in a report on Friday, April 11th.

Theratechnologies Trading Down 3.5 %

Shares of TH opened at C$3.58 on Wednesday. Theratechnologies has a fifty-two week low of C$1.59 and a fifty-two week high of C$4.33. The company has a market capitalization of C$114.22 million, a PE ratio of -40.52, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73. The stock has a fifty day moving average of C$2.39 and a two-hundred day moving average of C$2.18. The company has a debt-to-equity ratio of -293.92, a quick ratio of 0.64 and a current ratio of 1.08.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.